IPSC.mesodermal_primed: Studies — page 12
How association tiers are defined — cell–trait and gene–trait
SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.
Cell–trait tiers
- Cell–trait links
- Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
- Required for Specific or Relevant
- The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
- Specific (Tier 1)
- Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
- Relevant (Tier 2)
- Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
- Interpretation and report values
- CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
- Meta traits and individual traits
- Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.
Gene–trait priorities (variant–tCRE–gene evidence)
- Variant–tCRE–gene links
- Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
- Required genetic support
- The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
- Required cellular support
- The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
- High priority
- Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
- Medium priority
- Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
- Same-record evidence and aggregation
- Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
- Limits of interpretation
- A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.
State · 1,329 full-atlas cells · all tissues.
Marker genes and cell annotation · Open this population in Cell Browser →
ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.
Rows 11,001–12,000 of 12,313; ranked by score descending. Equal values use name/identifier order.
| # | Trait / study | Individual trait ID | Mean IC score |
|---|---|---|---|
| 11001 | DCTN1/ERBIN ratio | GCST90314429 | 3.21e-04 |
| 11002 | GNLY/GZMA ratio | GCST90314949 | 3.18e-04 |
| 11003 | Mandibular retrognathia | FING00000784 | 3.18e-04 |
| 11004 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 3.18e-04 |
| 11005 | LIFR levels | GCST90469769 | 3.17e-04 |
| 11006 | CTSD levels | GCST90468910 | 3.16e-04 |
| 11007 | AmygNuclei lh volume Accessory-Basal-nucleus | GCST90002650 | 3.15e-04 |
| 11008 | FGF21/LEP ratio | GCST90314810 | 3.14e-04 |
| 11009 | ENPP2/TNFRSF11B ratio | GCST90314672 | 3.13e-04 |
| 11010 | EGF/PPIB ratio | GCST90314612 | 3.12e-04 |
| 11011 | ANGPT1/APP ratio | GCST90313260 | 3.12e-04 |
| 11012 | Gallstone disease | GCST90128518 | 3.11e-04 |
| 11013 | MGLL/PTPN6 ratio | GCST90315440 | 3.10e-04 |
| 11014 | PFKFB2 levels | GCST90470215 | 3.09e-04 |
| 11015 | IRAG2/TBC1D23 ratio | GCST90315191 | 3.05e-04 |
| 11016 | Type 1 diabetes | GCST90014023 | 3.04e-04 |
| 11017 | NUBP1 levels | GCST90470100 | 3.04e-04 |
| 11018 | DTI TBSS MD Anterior corona radiata R | GCST90384594 | 3.01e-04 |
| 11019 | Glaucoma (primary open-angle) | GCST90399725 | 3.01e-04 |
| 11020 | Left-hemisphere salience/ventral attention network to hippocampus white-matter structural connectivity | GCST90302723 | 3.01e-04 |
| 11021 | Cough on most days | Medical information | UKBB00000153 | 2.99e-04 |
| 11022 | F2R levels | GCST90012010 | 2.99e-04 |
| 11023 | SUSD2 levels | GCST90470787 | 2.98e-04 |
| 11024 | ESAM/SORT1 ratio | GCST90314716 | 2.98e-04 |
| 11025 | Job involved shift work | Employment history | UKBB00000382 | 2.98e-04 |
| 11026 | CRTAM/VCAM1 ratio | GCST90314281 | 2.97e-04 |
| 11027 | CCL2 levels | GCST90012007 | 2.96e-04 |
| 11028 | CLMP/GFRA1 ratio | GCST90314133 | 2.94e-04 |
| 11029 | Bone marrow fat fraction of left proximal femur | GCST90652392 | 2.94e-04 |
| 11030 | GADD45GIP1 levels | GCST90469293 | 2.94e-04 |
| 11031 | QDPR/THOP1 ratio | GCST90315757 | 2.93e-04 |
| 11032 | Graves' disease | GCST90018627 | 2.92e-04 |
| 11033 | DAPP1/SDC4 ratio | GCST90314399 | 2.92e-04 |
| 11034 | Omega-3 fatty acids to total fatty acids percentage | GCST90502466 | 2.91e-04 |
| 11035 | DCTN6 levels | GCST90468960 | 2.91e-04 |
| 11036 | GZMA/GZMH ratio | GCST90315008 | 2.90e-04 |
| 11037 | CPXM1/MDK ratio | GCST90314221 | 2.90e-04 |
| 11038 | Squamous cell carcinoma (PheCode 172.22) | GCST90475583 | 2.90e-04 |
| 11039 | MEGF9/MET ratio | GCST90315418 | 2.89e-04 |
| 11040 | CLPS/PRSS2 ratio | GCST90314141 | 2.88e-04 |
| 11041 | Repeated disturbing thoughts of stressful experience in past month | Traumatic events | UKBB00000750 | 2.87e-04 |
| 11042 | DTI TBSS FA Corticospinal tract R | GCST90384386 | 2.87e-04 |
| 11043 | Haematocrit percentage (UKB data field 30030) | GCST90468073 | 2.87e-04 |
| 11044 | ANGPT1/DKK1 ratio | GCST90313263 | 2.87e-04 |
| 11045 | CRYGD levels | GCST90468876 | 2.87e-04 |
| 11046 | CASP10 levels | GCST90468542 | 2.87e-04 |
| 11047 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T448 | ECGU000448 | 2.86e-04 |
| 11048 | NCK2/VASH1 ratio | GCST90315526 | 2.85e-04 |
| 11049 | CST3/TIMP1 ratio | GCST90314300 | 2.84e-04 |
| 11050 | CST3/RETN ratio | GCST90314297 | 2.80e-04 |
| 11051 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 2.80e-04 |
| 11052 | C7 levels | GCST90468502 | 2.79e-04 |
| 11053 | Plasma homoarginine levels in chronic kidney disease | GCST90265345 | 2.78e-04 |
| 11054 | CPXM1/LGMN ratio | GCST90314220 | 2.77e-04 |
| 11055 | CD70 levels | GCST90468645 | 2.77e-04 |
| 11056 | OPHN1 levels | GCST90470126 | 2.77e-04 |
| 11057 | eosinophil (absolute count, mean, inv-norm transformed) | GCST90475291 | 2.74e-04 |
| 11058 | DNAJA2/PRDX5 ratio | GCST90314506 | 2.74e-04 |
| 11059 | CANT1/HSPB1 ratio | GCST90313617 | 2.74e-04 |
| 11060 | Glaucoma | GCST90475383 | 2.73e-04 |
| 11061 | DNMBP/TJAP1 ratio | GCST90314521 | 2.72e-04 |
| 11062 | IQGAP2/STX4 ratio | GCST90315190 | 2.71e-04 |
| 11063 | Lysophosphatidylcholine (22:6) [sn2] levels | GCST90024185 | 2.71e-04 |
| 11064 | Acylcarnitine (18:2) levels | GCST90024623 | 2.70e-04 |
| 11065 | SDC4/SERPINE1 ratio | GCST90315819 | 2.69e-04 |
| 11066 | DTI TBSS L3 Genu of corpus callosum | GCST90384526 | 2.67e-04 |
| 11067 | C36:4 Phosphatidylethanolamine levels in chronic kidney disease | GCST90257357 | 2.67e-04 |
| 11068 | ATP5IF1/FIS1 ratio | GCST90313385 | 2.66e-04 |
| 11069 | VSTM2B levels | GCST90471056 | 2.65e-04 |
| 11070 | BCR/FOXO1 ratio | GCST90313490 | 2.64e-04 |
| 11071 | Cholesterol levels in very large HDL | GCST90500322 | 2.64e-04 |
| 11072 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 2.64e-04 |
| 11073 | Hypoplasia of dental enamel, including avohilmo | FING00000652 | 2.63e-04 |
| 11074 | F2R/GP6 ratio | GCST90314730 | 2.61e-04 |
| 11075 | Cerebrospinal fluid 3-hydroxy-2-ethylpropionate levels | GCST90317964 | 2.61e-04 |
| 11076 | Other arthritis (FG) | FING00000964 | 2.61e-04 |
| 11077 | FCRL5 levels | GCST90469208 | 2.60e-04 |
| 11078 | Benign neoplasm of other and unspecified endocrine glands | FING00000159 | 2.60e-04 |
| 11079 | AKT1S1/FHIT ratio | GCST90313228 | 2.59e-04 |
| 11080 | IDP dMRI TBSS MD Corticospinal tract R | GCST90004033 | 2.59e-04 |
| 11081 | Bronchitis | FING00000228 | 2.58e-04 |
| 11082 | CD83/IL12A_IL12B ratio | GCST90313905 | 2.58e-04 |
| 11083 | DSC2/EFEMP1 ratio | GCST90314555 | 2.58e-04 |
| 11084 | CLEC1B/DAB2 ratio | GCST90314086 | 2.58e-04 |
| 11085 | aseg rh number HolesBeforeFixing | GCST90002647 | 2.57e-04 |
| 11086 | CST3/TAFA5 ratio | GCST90314298 | 2.56e-04 |
| 11087 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 97) | GCST90320660 | 2.55e-04 |
| 11088 | Cholesterol levels in small HDL | GCST90092944 | 2.55e-04 |
| 11089 | KLRD1/LY9 ratio | GCST90315261 | 2.55e-04 |
| 11090 | Acute pancreatitis | GCST90255375 | 2.54e-04 |
| 11091 | CRNN levels | GCST90468869 | 2.54e-04 |
| 11092 | All dysplastic lesions of the cervix uteri, vagina or vulva | FING00000061 | 2.54e-04 |
| 11093 | Sum eosinophil basophil counts | GCST004624 | 2.52e-04 |
| 11094 | CDH1/CDH17 ratio | GCST90313945 | 2.50e-04 |
| 11095 | GP1BA/SELP ratio | GCST90314958 | 2.50e-04 |
| 11096 | USP25 levels | GCST90471019 | 2.50e-04 |
| 11097 | Omega-3 fatty acid levels | GCST90502440 | 2.50e-04 |
| 11098 | Sphingomyelin (d18:1/20:0, d16:1/22:0) levels | GCST90200001 | 2.50e-04 |
| 11099 | CCL20 levels | GCST90468572 | 2.49e-04 |
| 11100 | RGS10 levels | GCST90470465 | 2.49e-04 |
| 11101 | FASLG levels | GCST90469191 | 2.49e-04 |
| 11102 | CHCHD6 levels | GCST90468739 | 2.48e-04 |
| 11103 | PLA2G15 levels | GCST90470245 | 2.48e-04 |
| 11104 | Chronic diseases of tonsils and adenoids | FING00000283 | 2.47e-04 |
| 11105 | KLK6/PTPRN2 ratio | GCST90315256 | 2.47e-04 |
| 11106 | Acute appendicitis, with complications | FING00000019 | 2.47e-04 |
| 11107 | DLG4 levels | GCST90469001 | 2.46e-04 |
| 11108 | CCL24 levels | GCST90468576 | 2.45e-04 |
| 11109 | BTN3A2 levels | GCST90468481 | 2.44e-04 |
| 11110 | Noninflammatory disorders of female genital tract | FING00000882 | 2.44e-04 |
| 11111 | GOPC levels | GCST90469377 | 2.43e-04 |
| 11112 | AP3B1 levels | GCST90468325 | 2.43e-04 |
| 11113 | PCDH1 levels | GCST90470170 | 2.43e-04 |
| 11114 | Concentration of medium HDL particles | GCST90498622 | 2.43e-04 |
| 11115 | 1-margaroyl-2-linoleoyl-GPC (17:0/18:2) metabolite level | GCST90616013 | 2.42e-04 |
| 11116 | Other hypothyroidism | Disorders of thyroid gland | UKBB00000611 | 2.42e-04 |
| 11117 | F2R/SPINT2 ratio | GCST90314737 | 2.42e-04 |
| 11118 | Right ventricular stroke volume (MTAG) | GCST90134594 | 2.41e-04 |
| 11119 | Asthma | Chronic lower respiratory diseases | UKBB00000053 | 2.41e-04 |
| 11120 | TSC22D1 levels | GCST90470973 | 2.41e-04 |
| 11121 | Asthma | respiratory | UKBB00000054 | 2.40e-04 |
| 11122 | CD209/GP2 ratio | GCST90313751 | 2.40e-04 |
| 11123 | CC2D1A/WWP2 ratio | GCST90313668 | 2.40e-04 |
| 11124 | STX8 levels | GCST90470776 | 2.40e-04 |
| 11125 | CANT1/GSTA1 ratio | GCST90313616 | 2.39e-04 |
| 11126 | Ulcerative colitis (PheCode 555.2) | GCST90044155 | 2.38e-04 |
| 11127 | Primary biliary cholangitis | GCST90061440 | 2.37e-04 |
| 11128 | MYCT1 levels | GCST90618046 | 2.37e-04 |
| 11129 | ITGAM levels | GCST90469638 | 2.37e-04 |
| 11130 | RRM2 levels | GCST90470501 | 2.37e-04 |
| 11131 | ACADSB levels | GCST90468195 | 2.36e-04 |
| 11132 | CALCOCO1/TBC1D5 ratio | GCST90313610 | 2.35e-04 |
| 11133 | CFI levels | GCST90468730 | 2.35e-04 |
| 11134 | Sarcoidosis | GCST90503483 | 2.34e-04 |
| 11135 | PDGFA/SNAP23 ratio | GCST90315619 | 2.33e-04 |
| 11136 | Hypothyroidism NOS | endocrine/metabolic | UKBB00000336 | 2.32e-04 |
| 11137 | GRAP2/SNX9 ratio | GCST90314988 | 2.32e-04 |
| 11138 | SERPINB6/TXNDC5 ratio | GCST90315832 | 2.32e-04 |
| 11139 | Dermatitis and eczema | FING00000402 | 2.31e-04 |
| 11140 | GZMA/TNFRSF8 ratio | GCST90315014 | 2.31e-04 |
| 11141 | Asthma | GCST90018575 | 2.30e-04 |
| 11142 | Chromatiales abundance in stool | GCST90032318 | 2.30e-04 |
| 11143 | Urinary calculus (PheCode 594) | GCST90476143 | 2.29e-04 |
| 11144 | IL3RA levels | GCST90469596 | 2.29e-04 |
| 11145 | Paraproteinemia (PheCode 270.32) | GCST90475710 | 2.28e-04 |
| 11146 | MESD/SNX9 ratio | GCST90315423 | 2.28e-04 |
| 11147 | Operative procedures - Injection of therapeutic substance into joint | Summary Operations | UKBB00000582 | 2.28e-04 |
| 11148 | Calcium levels (UKB data field 30680) | GCST90468065 | 2.27e-04 |
| 11149 | CLSTN3 levels | GCST90468790 | 2.26e-04 |
| 11150 | IGF1 levels | GCST90468078 | 2.24e-04 |
| 11151 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502069 | 2.23e-04 |
| 11152 | CD2AP levels | GCST90468617 | 2.23e-04 |
| 11153 | BID levels | GCST90468444 | 2.23e-04 |
| 11154 | APOA1 levels | GCST90497122 | 2.21e-04 |
| 11155 | GOPC/IRAK4 ratio | GCST90314954 | 2.21e-04 |
| 11156 | CEACAM6 levels | GCST90468697 | 2.20e-04 |
| 11157 | IL32 levels | GCST90469591 | 2.20e-04 |
| 11158 | CHI3L1/HSPG2 ratio | GCST90314043 | 2.20e-04 |
| 11159 | RABEP1 levels | GCST90470414 | 2.19e-04 |
| 11160 | KITLG/PLTP ratio | GCST90315252 | 2.19e-04 |
| 11161 | PDLIM7/TBC1D23 ratio | GCST90315640 | 2.18e-04 |
| 11162 | PILRA/TNFRSF1A ratio | GCST90315655 | 2.17e-04 |
| 11163 | CD164 levels | GCST90468602 | 2.17e-04 |
| 11164 | CST3/IL18BP ratio | GCST90314294 | 2.16e-04 |
| 11165 | Lymphocyte count | GCST90018742 | 2.15e-04 |
| 11166 | Femoral hernia | FING00000540 | 2.15e-04 |
| 11167 | Eosinophill count (UKB data field 30150) | GCST90468068 | 2.15e-04 |
| 11168 | CD59/PI3 ratio | GCST90313858 | 2.14e-04 |
| 11169 | STK4 levels | GCST90470767 | 2.14e-04 |
| 11170 | CKAP4/PGF ratio | GCST90314075 | 2.12e-04 |
| 11171 | PTPN1/WWP2 ratio | GCST90315746 | 2.11e-04 |
| 11172 | FUT8/VEGFC ratio | GCST90314896 | 2.11e-04 |
| 11173 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditions | UKBB00000101 | 2.10e-04 |
| 11174 | CD48/SLAMF7 ratio | GCST90313842 | 2.10e-04 |
| 11175 | Rheumatoid arthritis | GCST90132224 | 2.10e-04 |
| 11176 | SDC4 levels | GCST90470559 | 2.10e-04 |
| 11177 | MITD1/SNX9 ratio | GCST90315454 | 2.10e-04 |
| 11178 | C19ORF12 levels | GCST90468483 | 2.09e-04 |
| 11179 | Liver liking | GCST90094794 | 2.08e-04 |
| 11180 | HPSE levels | GCST90469473 | 2.08e-04 |
| 11181 | Later onset COPD | FING00000714 | 2.07e-04 |
| 11182 | CD40/ITGB5 ratio | GCST90313816 | 2.07e-04 |
| 11183 | EDAR/TMSB10 ratio | GCST90314590 | 2.06e-04 |
| 11184 | Other/unspecified rheumatoid arthritis | FING00001126 | 2.06e-04 |
| 11185 | F2R/ITGB1BP2 ratio | GCST90314731 | 2.04e-04 |
| 11186 | PRKAR2A levels | GCST90470327 | 2.03e-04 |
| 11187 | MITD1/WWP2 ratio | GCST90315458 | 2.03e-04 |
| 11188 | DNAJC9 levels | GCST90469018 | 2.02e-04 |
| 11189 | IFNLR1 levels | GCST90469518 | 2.02e-04 |
| 11190 | Other Crohn's disease | FING00000992 | 2.01e-04 |
| 11191 | GFRA1/TNFRSF1A ratio | GCST90314924 | 2.01e-04 |
| 11192 | CTSZ/SMPDL3A ratio | GCST90314322 | 2.01e-04 |
| 11193 | Psoriatic arthritis | GCST90243956 | 2.00e-04 |
| 11194 | Operative procedures - Anastomosis of mammary artery to left anterior descending coronary artery | Summary Operations | UKBB00000571 | 1.99e-04 |
| 11195 | CD160/CXCL16 ratio | GCST90313728 | 1.99e-04 |
| 11196 | Principal component-derived dietary pattern 21 | GCST90133026 | 1.99e-04 |
| 11197 | HTRA2/TRIAP1 ratio | GCST90315099 | 1.98e-04 |
| 11198 | JAM3 levels | GCST90469660 | 1.98e-04 |
| 11199 | CASP1 levels | GCST90468543 | 1.96e-04 |
| 11200 | Carnitine levels | GCST90243481 | 1.96e-04 |
| 11201 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 1.96e-04 |
| 11202 | PCDH9 levels | GCST90470172 | 1.96e-04 |
| 11203 | EDAR/SDC4 ratio | GCST90314585 | 1.96e-04 |
| 11204 | Free cholesterol to total lipids ratio in large VLDL | GCST90092873 | 1.95e-04 |
| 11205 | rfMRI connectivity (ICA100 edge 605) | GCST90005458 | 1.94e-04 |
| 11206 | PODXL levels | GCST90470280 | 1.93e-04 |
| 11207 | TNFRSF14 levels | GCST90470907 | 1.93e-04 |
| 11208 | VEGFC/ZBTB16 ratio | GCST90315946 | 1.92e-04 |
| 11209 | Frequency of heavy DIY in last 4 weeks | Physical activity | UKBB00000263 | 1.92e-04 |
| 11210 | X-12707 levels | GCST90200502 | 1.91e-04 |
| 11211 | CLC levels | GCST90468762 | 1.91e-04 |
| 11212 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 1.88e-04 |
| 11213 | CCL22/PDGFB ratio | GCST90313692 | 1.87e-04 |
| 11214 | T1 FreeSurfer a2009s rh S temporal sup volume | GCST90385110 | 1.86e-04 |
| 11215 | Lysophosphatidylcholine (26:0) [sn1] levels | GCST90025427 | 1.86e-04 |
| 11216 | APOH levels | GCST90468340 | 1.85e-04 |
| 11217 | CEACAM20 levels | GCST90468693 | 1.85e-04 |
| 11218 | CHGB levels | GCST90468742 | 1.85e-04 |
| 11219 | Right bundle branch block (PheCode 426.31) | GCST90475957 | 1.85e-04 |
| 11220 | FHIT/MAX ratio | GCST90314818 | 1.85e-04 |
| 11221 | DKK4 levels | GCST90468999 | 1.84e-04 |
| 11222 | ACVRL1/TNFRSF9 ratio | GCST90313160 | 1.83e-04 |
| 11223 | pro-brain natriuretic peptide (proBNP, mean, inv-norm transformed) | GCST90476312 | 1.83e-04 |
| 11224 | BCL2L15 levels | GCST90468431 | 1.83e-04 |
| 11225 | Respiratory disease (confirmatory factor analysis Factor 11) | GCST90309345 | 1.82e-04 |
| 11226 | Plasma methylsuccinoylcarnitine levels in chronic kidney disease | GCST90265508 | 1.82e-04 |
| 11227 | ITGB5/SIAE ratio | GCST90315234 | 1.82e-04 |
| 11228 | Ulcerative ileocolitis | FING00001392 | 1.82e-04 |
| 11229 | MIA levels | GCST90469903 | 1.81e-04 |
| 11230 | EGLN1 levels | GCST90469087 | 1.80e-04 |
| 11231 | Mean reticulocyte volume | Blood count | UKBB00000451 | 1.79e-04 |
| 11232 | CD58/IFNGR1 ratio | GCST90313849 | 1.78e-04 |
| 11233 | CALCOCO1/CRACR2A ratio | GCST90313598 | 1.78e-04 |
| 11234 | PEAR1/SPINT2 ratio | GCST90315644 | 1.77e-04 |
| 11235 | IDP dMRI TBSS L1 Corticospinal tract R | GCST90004081 | 1.77e-04 |
| 11236 | Urine adenosine levels in chronic kidney disease | GCST90264757 | 1.75e-04 |
| 11237 | TCN1 levels | GCST90470819 | 1.75e-04 |
| 11238 | GSN levels | GCST90469409 | 1.74e-04 |
| 11239 | SCPEP1 levels | GCST90470553 | 1.74e-04 |
| 11240 | Concentration of large HDL particles | GCST90497836 | 1.74e-04 |
| 11241 | APP/FKBP1B ratio | GCST90313323 | 1.72e-04 |
| 11242 | CCL23 levels | GCST90468575 | 1.72e-04 |
| 11243 | Total lipids in medium HDL | GCST90498604 | 1.71e-04 |
| 11244 | MMP9/PLTP ratio | GCST90315471 | 1.71e-04 |
| 11245 | Conjunctivitis | FING00000346 | 1.71e-04 |
| 11246 | ADM levels | GCST90011996 | 1.71e-04 |
| 11247 | Asthma | GCST90475259 | 1.70e-04 |
| 11248 | A4GALT levels | GCST90427457 | 1.70e-04 |
| 11249 | Pregnenolone sulfate levels | GCST90199873 | 1.70e-04 |
| 11250 | TCL1A/TNFRSF13C ratio | GCST90315912 | 1.70e-04 |
| 11251 | Systemic connective tissue disorders | FING00001350 | 1.69e-04 |
| 11252 | TNFRSF1B levels | GCST90470911 | 1.69e-04 |
| 11253 | CD79B/TNFRSF4 ratio | GCST90313903 | 1.69e-04 |
| 11254 | ARHGEF12 levels | GCST90468358 | 1.68e-04 |
| 11255 | Anorexia (incl.atypical) | FING00000093 | 1.68e-04 |
| 11256 | EPHB4/ESAM ratio | GCST90314679 | 1.67e-04 |
| 11257 | CD48/CRTAM ratio | GCST90313839 | 1.67e-04 |
| 11258 | Asthma (childhood onset) | GCST007800 | 1.66e-04 |
| 11259 | CA13/QDPR ratio | GCST90313564 | 1.66e-04 |
| 11260 | Coffee max liking | GCST90094739 | 1.66e-04 |
| 11261 | IDP T1 FIRST right pallidum volume | GCST90002443 | 1.65e-04 |
| 11262 | VPS4B levels | GCST90471047 | 1.64e-04 |
| 11263 | FCRL5/LY96 ratio | GCST90314803 | 1.63e-04 |
| 11264 | FCRL2/SEMA7A ratio | GCST90314800 | 1.63e-04 |
| 11265 | Prescriptions - prostaglandin analog | UKBB00000697 | 1.63e-04 |
| 11266 | CD55/ITGB1 ratio | GCST90313846 | 1.62e-04 |
| 11267 | SCARF1/TNFRSF14 ratio | GCST90315812 | 1.61e-04 |
| 11268 | ECHS1 levels | GCST90469063 | 1.59e-04 |
| 11269 | neutrophil (fraction, minimum, inv-norm transformed) | GCST90475541 | 1.59e-04 |
| 11270 | PDGFA/PLA2G4A ratio | GCST90315615 | 1.59e-04 |
| 11271 | ITGB5/VSIR ratio | GCST90315235 | 1.59e-04 |
| 11272 | Omega-6 fatty acid levels | GCST90502519 | 1.58e-04 |
| 11273 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 1.58e-04 |
| 11274 | VEGFD levels | GCST90471037 | 1.58e-04 |
| 11275 | Atopic dermatitis | GCST90027161 | 1.57e-04 |
| 11276 | KIFBP/TBC1D23 ratio | GCST90315250 | 1.57e-04 |
| 11277 | CD69/F2R ratio | GCST90313877 | 1.57e-04 |
| 11278 | BAG3 levels | GCST90468416 | 1.57e-04 |
| 11279 | F2R/TNFRSF14 ratio | GCST90314739 | 1.56e-04 |
| 11280 | IST1 levels | GCST90469632 | 1.56e-04 |
| 11281 | lymphocyte (fraction, maximum, inv-norm transformed) | GCST90475432 | 1.55e-04 |
| 11282 | APRT/MIF ratio | GCST90313336 | 1.55e-04 |
| 11283 | eosinophil (absolute count, maximum, inv-norm transformed) | GCST90475288 | 1.55e-04 |
| 11284 | Breast cancer (triple negative or BRCA1-positive) | GCST010100 | 1.55e-04 |
| 11285 | ICAM3/SLAMF7 ratio | GCST90315123 | 1.55e-04 |
| 11286 | Triacylglycerol_47:4_[M+NH4]1+ levels | GCST90060391 | 1.54e-04 |
| 11287 | SPOCK1 levels | GCST90470730 | 1.54e-04 |
| 11288 | Prostate cancer | GCST90011808 | 1.53e-04 |
| 11289 | CD160/NCR1 ratio | GCST90313732 | 1.53e-04 |
| 11290 | Adenocarcinoma and papilloma adenocarcinoma of rectum | FING00000039 | 1.53e-04 |
| 11291 | Free cholesterol in small HDL (UKB data field 23577) | GCST90269674 | 1.53e-04 |
| 11292 | ICD10 N87: Dysplasia of cervix uteri | GCST90454218 | 1.52e-04 |
| 11293 | Crohn's disease of small intestine | FING00000369 | 1.52e-04 |
| 11294 | CACYBP levels | GCST90468524 | 1.52e-04 |
| 11295 | CCL2/CCL7 ratio | GCST90313696 | 1.52e-04 |
| 11296 | CD83 levels | GCST90468652 | 1.51e-04 |
| 11297 | Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555) | GCST90476065 | 1.51e-04 |
| 11298 | HSPG2/VASN ratio | GCST90315094 | 1.51e-04 |
| 11299 | DBNL/HSPA1A ratio | GCST90314418 | 1.51e-04 |
| 11300 | METAP2/PLPBP ratio | GCST90315432 | 1.50e-04 |
| 11301 | CTRB1/KIRREL2 ratio | GCST90314306 | 1.50e-04 |
| 11302 | Dementia due to Parkinson's disease (more control exclusions) | FING00000392 | 1.50e-04 |
| 11303 | Mean platelet volume during third trimester of pregnancy | GCST90302231 | 1.49e-04 |
| 11304 | Right ventricular peak atrial filling rate | GCST90268119 | 1.49e-04 |
| 11305 | CTSV levels | GCST90468917 | 1.49e-04 |
| 11306 | CD69/NFATC1 ratio | GCST90313879 | 1.49e-04 |
| 11307 | IL22 levels | GCST90469582 | 1.49e-04 |
| 11308 | FCGR2A levels | GCST90469200 | 1.49e-04 |
| 11309 | BACH1/CNST ratio | GCST90313436 | 1.48e-04 |
| 11310 | Docosahexaenoic acid levels | GCST90502259 | 1.48e-04 |
| 11311 | CDON/SCARA5 ratio | GCST90313995 | 1.47e-04 |
| 11312 | BSG/CKAP4 ratio | GCST90313531 | 1.47e-04 |
| 11313 | IPCEF1/SPARC ratio | GCST90315186 | 1.47e-04 |
| 11314 | Other peripheral vertigo | FING00001088 | 1.46e-04 |
| 11315 | Ceramide (d18:1/24:0) levels | GCST90024046 | 1.46e-04 |
| 11316 | Estimated glomerular filtration rate (creatinine) | GCST90103634 | 1.46e-04 |
| 11317 | ATRN levels | GCST90468400 | 1.45e-04 |
| 11318 | Cholesterol to Total Lipids in Small HDL percentage | GCST90499373 | 1.45e-04 |
| 11319 | KLK11 levels | GCST90469697 | 1.44e-04 |
| 11320 | PDGFB/ST6GAL1 ratio | GCST90315630 | 1.44e-04 |
| 11321 | Bone marrow fat fraction of right proximal femur | GCST90652393 | 1.44e-04 |
| 11322 | DKK1/IPCEF1 ratio | GCST90314471 | 1.44e-04 |
| 11323 | rfMRI amplitudes (ICA100 node 30) | GCST90004618 | 1.43e-04 |
| 11324 | aseg global volume CC-Anterior | GCST90002611 | 1.43e-04 |
| 11325 | PATE4 levels | GCST90242405 | 1.43e-04 |
| 11326 | DBI/MESD ratio | GCST90314409 | 1.41e-04 |
| 11327 | DTI TBSS MO Medial lemniscus L | GCST90384629 | 1.41e-04 |
| 11328 | DECR1/METAP1D ratio | GCST90314448 | 1.40e-04 |
| 11329 | CLEC1B/SORT1 ratio | GCST90314104 | 1.40e-04 |
| 11330 | Lymphocyte count | GCST90002317 | 1.40e-04 |
| 11331 | Dermatomycosis (PheCode 110.2) | GCST90475565 | 1.40e-04 |
| 11332 | ANGPT1/CCN2 ratio | GCST90313261 | 1.39e-04 |
| 11333 | Average diameter for HDL particles | GCST90497446 | 1.38e-04 |
| 11334 | UGDH levels | GCST90471006 | 1.38e-04 |
| 11335 | EPHB6/LAYN ratio | GCST90314681 | 1.38e-04 |
| 11336 | PTX3 levels | GCST90470392 | 1.38e-04 |
| 11337 | Varicose veins | GCST90086144 | 1.37e-04 |
| 11338 | F-carbohydrate liking (derived food-liking factor) | GCST90094725 | 1.37e-04 |
| 11339 | Carcinoma in situ of breast, intraductal (controls excluding all cancers) | FING00000240 | 1.37e-04 |
| 11340 | PDGFB/SNAP29 ratio | GCST90315627 | 1.36e-04 |
| 11341 | BCR/CLIP2 ratio | GCST90313486 | 1.36e-04 |
| 11342 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502414 | 1.36e-04 |
| 11343 | KLK10 levels | GCST90469696 | 1.36e-04 |
| 11344 | ERBB2/FURIN ratio | GCST90314686 | 1.35e-04 |
| 11345 | VWC2L levels | GCST90471063 | 1.35e-04 |
| 11346 | CLEC1B/LGALS8 ratio | GCST90314096 | 1.35e-04 |
| 11347 | CAMKK1/FOXO1 ratio | GCST90313613 | 1.35e-04 |
| 11348 | MMP12 levels | GCST90012070 | 1.35e-04 |
| 11349 | CLEC1B/HEXIM1 ratio | GCST90314093 | 1.34e-04 |
| 11350 | ALB levels | GCST90092807 | 1.34e-04 |
| 11351 | TIMM8A levels | GCST90470868 | 1.33e-04 |
| 11352 | LGMN levels | GCST90469766 | 1.32e-04 |
| 11353 | Duodenal ulcer | FING00000481 | 1.32e-04 |
| 11354 | CD226 levels | GCST90468609 | 1.31e-04 |
| 11355 | KYNU levels | GCST90469722 | 1.31e-04 |
| 11356 | Adenocarcinoma, papilloma adenocarcinoma and mucinous carcinomas of rectum, excluding all cancers (controls excluding all cancers) | FING00000041 | 1.31e-04 |
| 11357 | Anterior thigh muscle fat infiltration percentage | GCST90267351 | 1.30e-04 |
| 11358 | CKAP4/LAMP3 ratio | GCST90314073 | 1.30e-04 |
| 11359 | Ectropion or entropion (PheCode 374.1) | GCST90475891 | 1.30e-04 |
| 11360 | FUT8/PDGFA ratio | GCST90314890 | 1.29e-04 |
| 11361 | ERBIN/TBC1D23 ratio | GCST90314698 | 1.29e-04 |
| 11362 | FGF23 levels | GCST90012022 | 1.29e-04 |
| 11363 | CD244/CRTAM ratio | GCST90313763 | 1.28e-04 |
| 11364 | LAT/SERPINE1 ratio | GCST90315287 | 1.28e-04 |
| 11365 | Infective dermatitis | FING00000673 | 1.27e-04 |
| 11366 | HDGF levels | GCST90469442 | 1.27e-04 |
| 11367 | Eosinophil count | GCST90025987 | 1.26e-04 |
| 11368 | Thyroid peroxidase antibody positivity in pregnancy | GCST90435202 | 1.25e-04 |
| 11369 | PALM3 levels | GCST90470153 | 1.25e-04 |
| 11370 | DKK1/VEGFC ratio | GCST90314484 | 1.25e-04 |
| 11371 | ENTPD5 levels | GCST90241024 | 1.25e-04 |
| 11372 | SERPINA4 levels | GCST90470584 | 1.25e-04 |
| 11373 | ITGB2 levels | GCST90469644 | 1.24e-04 |
| 11374 | MMP9/OSM ratio | GCST90315468 | 1.24e-04 |
| 11375 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditions | UKBB00000100 | 1.23e-04 |
| 11376 | CIAPIN1/SPARC ratio | GCST90314069 | 1.22e-04 |
| 11377 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 1.22e-04 |
| 11378 | SMPD3 levels | GCST90470685 | 1.22e-04 |
| 11379 | Lymphocyte count | GCST004627 | 1.22e-04 |
| 11380 | Concentration of small HDL particles (UKB data field 23572) | GCST90269669 | 1.22e-04 |
| 11381 | IDP dMRI TBSS MD Cerebral peduncle L | GCST90004042 | 1.21e-04 |
| 11382 | TIMM10 levels | GCST90470867 | 1.21e-04 |
| 11383 | Calculus of kidney (PheCode 594.1) | GCST90476145 | 1.21e-04 |
| 11384 | GIMAP7 levels | GCST90469345 | 1.20e-04 |
| 11385 | Skin sebum (glabella) | GCST90502797 | 1.20e-04 |
| 11386 | CELA3A/CPB1 ratio | GCST90314010 | 1.20e-04 |
| 11387 | CD99 levels | GCST90468658 | 1.19e-04 |
| 11388 | LGALS3BP levels | GCST90469760 | 1.18e-04 |
| 11389 | CD84/SORT1 ratio | GCST90313918 | 1.18e-04 |
| 11390 | SERPINB1/SERPINB9 ratio | GCST90315827 | 1.18e-04 |
| 11391 | XCL1 levels | GCST90471081 | 1.17e-04 |
| 11392 | IL1R2/MEGF9 ratio | GCST90315159 | 1.17e-04 |
| 11393 | MAPRE3 levels | GCST90469859 | 1.17e-04 |
| 11394 | FABP4/SNCG ratio | GCST90314759 | 1.17e-04 |
| 11395 | Neonatal jaundice (paternal effect) | GCST90435147 | 1.16e-04 |
| 11396 | EREG/F2R ratio | GCST90314700 | 1.15e-04 |
| 11397 | TCN2 levels | GCST90470820 | 1.15e-04 |
| 11398 | CD74/JAM2 ratio | GCST90313893 | 1.15e-04 |
| 11399 | Rheumatoid arthritis | musculoskeletal | UKBB00000757 | 1.15e-04 |
| 11400 | PHOSPHO1 levels | GCST90470227 | 1.14e-04 |
| 11401 | CDHR5 levels | GCST90468680 | 1.14e-04 |
| 11402 | Mean spheric corpuscular volume | GCST90002397 | 1.14e-04 |
| 11403 | CC2D1A/TMSB10 ratio | GCST90313667 | 1.14e-04 |
| 11404 | CLTA levels | GCST90468791 | 1.13e-04 |
| 11405 | SNX9/STIP1 ratio | GCST90315864 | 1.12e-04 |
| 11406 | Cholesterol in small HDL (UKB data field 23575) | GCST90269672 | 1.12e-04 |
| 11407 | DNMBP/PTPN1 ratio | GCST90314517 | 1.12e-04 |
| 11408 | CD48 levels | GCST90468635 | 1.12e-04 |
| 11409 | HS1BP3 levels | GCST90469477 | 1.11e-04 |
| 11410 | FLI1 levels | GCST90469247 | 1.11e-04 |
| 11411 | EDAR/F11R ratio | GCST90314576 | 1.11e-04 |
| 11412 | Treatment/medication code - levothyroxine sodium | Medications | UKBB00000849 | 1.10e-04 |
| 11413 | Rheumatoid arthritis | GCST90132223 | 1.10e-04 |
| 11414 | SERPINE1/SMAD1 ratio | GCST90315833 | 1.08e-04 |
| 11415 | CTSL levels | GCST90468914 | 1.08e-04 |
| 11416 | Glaucoma | GCST90468129 | 1.08e-04 |
| 11417 | STX4 levels | GCST90470772 | 1.07e-04 |
| 11418 | Allergic disease (asthma, hay fever or eczema) | GCST005038 | 1.07e-04 |
| 11419 | ADAMTS16 levels | GCST90468224 | 1.07e-04 |
| 11420 | VEGFB levels | GCST90471035 | 1.07e-04 |
| 11421 | Glycosyl ceramide (d18:1/20:0, d16:1/22:0) levels | GCST90200145 | 1.07e-04 |
| 11422 | PTRHD1 levels | GCST90470389 | 1.07e-04 |
| 11423 | Cholesteryl Esters in HDL | GCST90497368 | 1.07e-04 |
| 11424 | PECAM1 levels | GCST90470206 | 1.07e-04 |
| 11425 | CPVL levels | GCST90468848 | 1.06e-04 |
| 11426 | Glycine levels | GCST007638 | 1.05e-04 |
| 11427 | NBL1/NECTIN4 ratio | GCST90315514 | 1.05e-04 |
| 11428 | NMI levels | GCST90470056 | 1.05e-04 |
| 11429 | CRTAM/GZMA ratio | GCST90314275 | 1.05e-04 |
| 11430 | CD46/THBD ratio | GCST90313836 | 1.04e-04 |
| 11431 | LAIR2 levels | GCST90469729 | 1.03e-04 |
| 11432 | Cerebrospinal fluid S-1-pyrroline-5-carboxylate levels | GCST90318235 | 1.03e-04 |
| 11433 | Cholesterol to total lipids in very large HDL percentage (UKB data field 23630) | GCST90269727 | 1.02e-04 |
| 11434 | Right ventricular stroke volume | GCST90134590 | 1.02e-04 |
| 11435 | PDGFB/PTPN6 ratio | GCST90315625 | 1.02e-04 |
| 11436 | Asthma | GCST010042 | 1.02e-04 |
| 11437 | PGD levels | GCST90470217 | 1.01e-04 |
| 11438 | HDL cholesterol levels | GCST90497352 | 1.01e-04 |
| 11439 | EDAR/SPARC ratio | GCST90314588 | 1.01e-04 |
| 11440 | BAG6/USP8 ratio | GCST90313451 | 1.01e-04 |
| 11441 | Diverticulitis | GCST90468125 | 1.00e-04 |
| 11442 | HAVCR2 levels | GCST90421515 | 9.99e-05 |
| 11443 | neutrophil (fraction, mean, inv-norm transformed) | GCST90475538 | 9.96e-05 |
| 11444 | Psoriasis | FING00001222 | 9.93e-05 |
| 11445 | Gestational [pregnancy-induced] oedema and proteinuria without hypertension | FING00000572 | 9.92e-05 |
| 11446 | Seen a psychiatrist for nerves, anxiety, tension or depression | Mental health | UKBB00000764 | 9.89e-05 |
| 11447 | Cerotoylcarnitine (C26) levels | GCST90200136 | 9.85e-05 |
| 11448 | BCR/VASH1 ratio | GCST90313499 | 9.83e-05 |
| 11449 | GLO1 levels | GCST90469358 | 9.82e-05 |
| 11450 | CLEC1B/SNAP29 ratio | GCST90314103 | 9.81e-05 |
| 11451 | Mean sphered cell volume | Blood count | UKBB00000452 | 9.79e-05 |
| 11452 | ACOX1/VSIR ratio | GCST90313155 | 9.71e-05 |
| 11453 | ILKAP levels | GCST90469608 | 9.70e-05 |
| 11454 | INHBB levels | GCST90469614 | 9.70e-05 |
| 11455 | Rosacea (PheCode 695.3) | GCST90476178 | 9.69e-05 |
| 11456 | TNFSF13B levels | GCST90470920 | 9.64e-05 |
| 11457 | ENO2/MANF ratio | GCST90314662 | 9.59e-05 |
| 11458 | CLEC1B/TXNDC5 ratio | GCST90314105 | 9.58e-05 |
| 11459 | PARP1 levels | GCST90470160 | 9.54e-05 |
| 11460 | SIGLEC10 levels | GCST90470630 | 9.44e-05 |
| 11461 | Free cholesterol in HDL (UKB data field 23422) | GCST90269519 | 9.42e-05 |
| 11462 | CD55/CHI3L1 ratio | GCST90313845 | 9.41e-05 |
| 11463 | Other systemic involvement of connective tissue (FG) | FING00001116 | 9.40e-05 |
| 11464 | SIGLEC8 levels | GCST90470636 | 9.37e-05 |
| 11465 | Urticaria | GCST90018716 | 9.35e-05 |
| 11466 | Acute upper respiratory infections of multiple and unspecified sites | FING00000035 | 9.28e-05 |
| 11467 | ARHGEF12/IRAK4 ratio | GCST90313350 | 9.27e-05 |
| 11468 | Myocardial fractal dimension (slice 3) | GCST90000289 | 9.23e-05 |
| 11469 | HBEGF/PDGFB ratio | GCST90315034 | 9.21e-05 |
| 11470 | Usual side of head for mobile phone use - Equally left and right | Electronic device use | UKBB00000888 | 9.16e-05 |
| 11471 | CST6/NECTIN4 ratio | GCST90314303 | 9.15e-05 |
| 11472 | VSIR levels | GCST90471053 | 9.15e-05 |
| 11473 | IGFBP3 levels | GCST90469529 | 9.15e-05 |
| 11474 | DAB2/ERBIN ratio | GCST90314361 | 9.07e-05 |
| 11475 | PHACTR2 levels | GCST90470224 | 9.04e-05 |
| 11476 | CTRC/PLA2G1B ratio | GCST90314310 | 9.01e-05 |
| 11477 | IMPACT levels | GCST90469611 | 9.00e-05 |
| 11478 | KIT levels | GCST90469692 | 8.98e-05 |
| 11479 | IL5RA levels | GCST90469600 | 8.97e-05 |
| 11480 | Triacylglycerol_50:2_[M+NH4]1+ levels | GCST90060473 | 8.95e-05 |
| 11481 | Free cholesterol in large VLDL | GCST90498185 | 8.86e-05 |
| 11482 | Stable angina pectoris | GCST90018695 | 8.86e-05 |
| 11483 | Thyrotoxicosis | FING00001360 | 8.80e-05 |
| 11484 | 3,5-dichloro-2,6-dihydroxybenzoic acid levels | GCST90200252 | 8.80e-05 |
| 11485 | LAG3 levels | GCST90469727 | 8.80e-05 |
| 11486 | CA9/CBLIF ratio | GCST90313595 | 8.77e-05 |
| 11487 | ATP5IF1 levels | GCST90468392 | 8.75e-05 |
| 11488 | Volume of right cortico-amygdaloid transition area | GCST90475018 | 8.67e-05 |
| 11489 | FCRL6/GZMA ratio | GCST90314806 | 8.65e-05 |
| 11490 | Hypothyroidism | GCST90204167 | 8.64e-05 |
| 11491 | Citrate levels | GCST90243442 | 8.60e-05 |
| 11492 | DDAH1 levels | GCST90468966 | 8.56e-05 |
| 11493 | DKK1/MGLL ratio | GCST90314473 | 8.55e-05 |
| 11494 | SLAMF7/TXNDC15 ratio | GCST90315850 | 8.54e-05 |
| 11495 | PTPRM levels | GCST90470384 | 8.53e-05 |
| 11496 | Phosphatidylcholine diacyl C38:4 levels | GCST90240046 | 8.53e-05 |
| 11497 | PDIA4 levels | GCST90470195 | 8.51e-05 |
| 11498 | Savoury biscuit liking | GCST90094834 | 8.50e-05 |
| 11499 | COLEC12/TGFBR2 ratio | GCST90314186 | 8.42e-05 |
| 11500 | COL6A3/TAFA5 ratio | GCST90314180 | 8.40e-05 |
| 11501 | MILR1 levels | GCST90469907 | 8.28e-05 |
| 11502 | TWF2 levels | GCST90470987 | 8.26e-05 |
| 11503 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498580 | 8.25e-05 |
| 11504 | HGF/MMP9 ratio | GCST90315056 | 8.18e-05 |
| 11505 | Hypothyroidism | endocrine/metabolic | UKBB00000335 | 8.12e-05 |
| 11506 | CBLIF levels | GCST90468552 | 8.09e-05 |
| 11507 | GRAP2/PPP1R2 ratio | GCST90314985 | 8.08e-05 |
| 11508 | FCRL6 levels | GCST90469209 | 8.08e-05 |
| 11509 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 66) | GCST90320629 | 8.03e-05 |
| 11510 | ERP44/SUMF2 ratio | GCST90314710 | 8.02e-05 |
| 11511 | GNLY levels | GCST90469372 | 7.99e-05 |
| 11512 | F2R/PDGFB ratio | GCST90314733 | 7.92e-05 |
| 11513 | Body fat percentage | GCST90103752 | 7.87e-05 |
| 11514 | FGD3 levels | GCST90469217 | 7.82e-05 |
| 11515 | Spleen volume | GCST90016667 | 7.78e-05 |
| 11516 | RSPO1/RSPO3 ratio | GCST90315790 | 7.77e-05 |
| 11517 | DDHD2 levels | GCST90468968 | 7.77e-05 |
| 11518 | SNAP23/TXLNA ratio | GCST90315857 | 7.70e-05 |
| 11519 | SCAMP3/STX4 ratio | GCST90315805 | 7.66e-05 |
| 11520 | NUMB levels | GCST90470108 | 7.64e-05 |
| 11521 | ThalamNuclei lh volume Whole-thalamus | GCST90002762 | 7.61e-05 |
| 11522 | GATD3 levels | GCST90469309 | 7.59e-05 |
| 11523 | WFDC1 levels | GCST90471074 | 7.55e-05 |
| 11524 | REG1B/REG3A ratio | GCST90315765 | 7.54e-05 |
| 11525 | Concentration of large HDL particles (UKB data field 23558) | GCST90269655 | 7.54e-05 |
| 11526 | NPTX1 levels | GCST90470078 | 7.53e-05 |
| 11527 | Glaucoma | GCST90018632 | 7.48e-05 |
| 11528 | DAB2/VASH1 ratio | GCST90314369 | 7.43e-05 |
| 11529 | Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditions | UKBB00000518 | 7.42e-05 |
| 11530 | GPC1/ITGB6 ratio | GCST90314977 | 7.40e-05 |
| 11531 | AKT1S1/MAX ratio | GCST90313230 | 7.35e-05 |
| 11532 | Thyroid peroxidase antibody levels in pregnancy | GCST90435201 | 7.33e-05 |
| 11533 | CCL2 levels | GCST90468581 | 7.31e-05 |
| 11534 | Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels | GCST90060270 | 7.25e-05 |
| 11535 | Plasma pregnenetriol sulfate* levels in chronic kidney disease | GCST90265866 | 7.24e-05 |
| 11536 | PDGFB/PPP1R12A ratio | GCST90315623 | 7.21e-05 |
| 11537 | Lichen simplex chronicus and prurigo | FING00000725 | 7.19e-05 |
| 11538 | CNST/DOK2 ratio | GCST90314157 | 7.18e-05 |
| 11539 | PLXNB2/SEMA7A ratio | GCST90315692 | 7.15e-05 |
| 11540 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 7.15e-05 |
| 11541 | ATP5IF1/HSPA1A ratio | GCST90313388 | 7.15e-05 |
| 11542 | Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditions | UKBB00000509 | 7.15e-05 |
| 11543 | Free cholesterol levels in small HDL | GCST90092948 | 7.13e-05 |
| 11544 | ENG/TNFSF10 ratio | GCST90314651 | 7.13e-05 |
| 11545 | MS-disease / Multiple Sclerosis | FING00000839 | 7.08e-05 |
| 11546 | DTI TBSS L2 Genu of corpus callosum | GCST90384478 | 7.07e-05 |
| 11547 | Lymphocyte count | GCST90025984 | 7.06e-05 |
| 11548 | Phosphatidylcholine-O_40:5_[M+H]1+/Phosphatidylcholine-P_40:4_[M+H]1+ levels | GCST90060423 | 6.95e-05 |
| 11549 | TNFRSF17 levels | GCST90470908 | 6.92e-05 |
| 11550 | CRKL/MANF ratio | GCST90314269 | 6.89e-05 |
| 11551 | Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) | GCST90132227 | 6.84e-05 |
| 11552 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500506 | 6.79e-05 |
| 11553 | DTI autoptx FA unc r tract | GCST90385138 | 6.79e-05 |
| 11554 | Phosphatidylcholine-2O_32:0_[M+H]1+ levels | GCST90060244 | 6.78e-05 |
| 11555 | Adhesive capsulitis of shoulder | FING00000043 | 6.78e-05 |
| 11556 | Pilonidal cyst | FING00001167 | 6.72e-05 |
| 11557 | CLEC1B/PPP1R2 ratio | GCST90314101 | 6.66e-05 |
| 11558 | FCAR levels | GCST90469197 | 6.65e-05 |
| 11559 | Disorders of iron metabolism (PheCode 275.1) | GCST90475743 | 6.57e-05 |
| 11560 | HGF levels | GCST90469449 | 6.55e-05 |
| 11561 | ALB levels | GCST90475106 | 6.50e-05 |
| 11562 | ADAM22 levels | GCST90468218 | 6.49e-05 |
| 11563 | CA6 levels | GCST90468515 | 6.49e-05 |
| 11564 | FOLH1 levels | GCST90241272 | 6.48e-05 |
| 11565 | OGN levels | GCST90470119 | 6.45e-05 |
| 11566 | CSF3R levels | GCST90468885 | 6.42e-05 |
| 11567 | TBCA levels | GCST90470812 | 6.40e-05 |
| 11568 | Allergic asthma (mode) | FING00000066 | 6.38e-05 |
| 11569 | Plasma 1-methylurate levels in chronic kidney disease | GCST90264240 | 6.36e-05 |
| 11570 | ATG4A levels | GCST90468384 | 6.34e-05 |
| 11571 | RSPO3 levels | GCST90470504 | 6.32e-05 |
| 11572 | ESAM/JAM2 ratio | GCST90314712 | 6.29e-05 |
| 11573 | Principal component-derived dietary pattern 44 | GCST90133049 | 6.28e-05 |
| 11574 | Calcium | Blood biochemistry | UKBB00000114 | 6.26e-05 |
| 11575 | Asthma | GCST90014325 | 6.24e-05 |
| 11576 | FKBP5/MAP4K5 ratio | GCST90314843 | 6.18e-05 |
| 11577 | UROD levels | GCST90471016 | 6.08e-05 |
| 11578 | CSTB levels | GCST90468898 | 6.05e-05 |
| 11579 | Cholesteryl ester levels in small HDL | GCST90092946 | 6.03e-05 |
| 11580 | SNAP29/VEGFC ratio | GCST90315862 | 6.02e-05 |
| 11581 | CLEC1B/MGLL ratio | GCST90314097 | 6.01e-05 |
| 11582 | Non-cancer illness code, self-reported - asthma | Medical conditions | UKBB00000506 | 6.01e-05 |
| 11583 | PDGFA/VEGFC ratio | GCST90315622 | 6.00e-05 |
| 11584 | Free Cholesterol in HDL | GCST90497381 | 5.97e-05 |
| 11585 | Operation code - wisdom teeth surgery | Operations | UKBB00000569 | 5.95e-05 |
| 11586 | REG1A levels | GCST90470447 | 5.93e-05 |
| 11587 | CRELD2/F2R ratio | GCST90314254 | 5.90e-05 |
| 11588 | BSG/LAMP3 ratio | GCST90313533 | 5.88e-05 |
| 11589 | Methionine sulfone levels | GCST90199961 | 5.86e-05 |
| 11590 | DKK1/PPCDC ratio | GCST90314477 | 5.81e-05 |
| 11591 | CRADD/DARS1 ratio | GCST90314234 | 5.80e-05 |
| 11592 | PLA2G15/PRCP ratio | GCST90315661 | 5.80e-05 |
| 11593 | N6-acetyllysine levels in chronic kidney disease | GCST90257531 | 5.79e-05 |
| 11594 | DAG1/SCARF1 ratio | GCST90314381 | 5.75e-05 |
| 11595 | Non-albumin protein levels | UKBB00000503 | 5.74e-05 |
| 11596 | SOD2 levels | GCST90470705 | 5.72e-05 |
| 11597 | COL6A3 levels | GCST90468821 | 5.72e-05 |
| 11598 | Clonal hematopoiesis (overall) | GCST90435353 | 5.70e-05 |
| 11599 | ANGPT1/PDGFA ratio | GCST90313266 | 5.70e-05 |
| 11600 | ICOSLG levels | GCST90469503 | 5.69e-05 |
| 11601 | Asthma (adult onset) | GCST007799 | 5.67e-05 |
| 11602 | Noninfective enteritis and colitis | FING00000881 | 5.61e-05 |
| 11603 | CPB1/REG1A ratio | GCST90314212 | 5.60e-05 |
| 11604 | DCTN1/SCAMP3 ratio | GCST90314433 | 5.58e-05 |
| 11605 | Calculus of lower urinary tract (PheCode 594.2) | GCST90476146 | 5.55e-05 |
| 11606 | Attendance/disability/mobility allowance - None of the above | Other sociodemographic factors | UKBB00000059 | 5.55e-05 |
| 11607 | IL1RL2 levels | GCST90469575 | 5.54e-05 |
| 11608 | Concentration of large HDL particles | GCST90092851 | 5.54e-05 |
| 11609 | LAT2/SDC4 ratio | GCST90315278 | 5.50e-05 |
| 11610 | MAMDC4 levels | GCST90469842 | 5.50e-05 |
| 11611 | VAV3 levels | GCST90471030 | 5.49e-05 |
| 11612 | DKK1/VASH1 ratio | GCST90314482 | 5.48e-05 |
| 11613 | CALCOCO1/CASP8 ratio | GCST90313597 | 5.45e-05 |
| 11614 | Hair colour (natural, before greying) - Black | Sun exposure | UKBB00000295 | 5.45e-05 |
| 11615 | CLEC1B/RWDD1 ratio | GCST90314102 | 5.42e-05 |
| 11616 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 5.40e-05 |
| 11617 | Ulcerative colitis | GCST90476067 | 5.39e-05 |
| 11618 | Asthma | GCST90468112 | 5.38e-05 |
| 11619 | Mouth/teeth dental problems - Mouth ulcers | Mouth | UKBB00000488 | 5.35e-05 |
| 11620 | CLEC1B/NSFL1C ratio | GCST90314099 | 5.33e-05 |
| 11621 | SERPINB1 levels | GCST90470589 | 5.26e-05 |
| 11622 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 5.26e-05 |
| 11623 | CD48/FCRL6 ratio | GCST90313840 | 5.26e-05 |
| 11624 | CD164/CD99 ratio | GCST90313740 | 5.24e-05 |
| 11625 | ADGRE5/SEMA7A ratio | GCST90313183 | 5.20e-05 |
| 11626 | Arthropathies in other diseases classified elsewhere | FING00000108 | 5.18e-05 |
| 11627 | ARHGAP25/RNF41 ratio | GCST90313345 | 5.18e-05 |
| 11628 | PLEKHO1 levels | GCST90470256 | 5.17e-05 |
| 11629 | PAPPA levels | GCST90012036 | 5.16e-05 |
| 11630 | COLEC12 levels | GCST90468824 | 5.16e-05 |
| 11631 | CCS levels | GCST90468594 | 5.11e-05 |
| 11632 | CRACR2A/LBR ratio | GCST90314228 | 5.08e-05 |
| 11633 | MEGF9 levels | GCST90469884 | 5.08e-05 |
| 11634 | LSP1 levels | GCST90469811 | 5.04e-05 |
| 11635 | MARCO/SIGLEC1 ratio | GCST90315387 | 5.03e-05 |
| 11636 | KLRF1 levels | GCST90469712 | 4.96e-05 |
| 11637 | MDGA1 levels | GCST90469875 | 4.95e-05 |
| 11638 | PRSS2 levels | GCST90243126 | 4.89e-05 |
| 11639 | DPP6/SEZ6L2 ratio | GCST90314543 | 4.85e-05 |
| 11640 | Lymphocyte count | GCST90002388 | 4.85e-05 |
| 11641 | CD300A levels | GCST90468619 | 4.82e-05 |
| 11642 | Seronegative rheumatoid arthritis | FING00001296 | 4.82e-05 |
| 11643 | high density lipoprotein cholesterol (HDLC, minimm, inv-norm transformed) | GCST90475356 | 4.80e-05 |
| 11644 | Cucumber liking | GCST90094749 | 4.80e-05 |
| 11645 | EDN1 levels | GCST90469073 | 4.80e-05 |
| 11646 | NCS1 levels | GCST90470011 | 4.78e-05 |
| 11647 | FCRL2/LY9 ratio | GCST90314799 | 4.76e-05 |
| 11648 | CCL13/CCL2 ratio | GCST90313675 | 4.76e-05 |
| 11649 | FCGR2B levels | GCST90469201 | 4.73e-05 |
| 11650 | APP/DAG1 ratio | GCST90313320 | 4.70e-05 |
| 11651 | Diseases of external ear | FING00000424 | 4.69e-05 |
| 11652 | Charcot foot | FING00000268 | 4.68e-05 |
| 11653 | RPN1 levels | GCST90240964 | 4.68e-05 |
| 11654 | MPO levels | GCST90469937 | 4.67e-05 |
| 11655 | CD300E levels | GCST90468621 | 4.66e-05 |
| 11656 | RRAS levels | GCST90470499 | 4.63e-05 |
| 11657 | PDCD1LG2 levels | GCST90470180 | 4.63e-05 |
| 11658 | VAT1 levels | GCST90471029 | 4.61e-05 |
| 11659 | FLRT2 levels | GCST90469248 | 4.61e-05 |
| 11660 | ITGA5/SELE ratio | GCST90315205 | 4.59e-05 |
| 11661 | CCN2/SERPINB1 ratio | GCST90313715 | 4.58e-05 |
| 11662 | PDGFA/SCARF1 ratio | GCST90315617 | 4.57e-05 |
| 11663 | FHIT levels | GCST90469238 | 4.55e-05 |
| 11664 | PDGFB/USP8 ratio | GCST90315633 | 4.55e-05 |
| 11665 | KITLG levels | GCST90469691 | 4.50e-05 |
| 11666 | SORT1 levels | GCST90470710 | 4.44e-05 |
| 11667 | Recent feelings of inadequacy | Depression | UKBB00000739 | 4.41e-05 |
| 11668 | PSIP1 levels | GCST90470354 | 4.41e-05 |
| 11669 | MMP9 levels | GCST90469923 | 4.38e-05 |
| 11670 | CDKN2D levels | GCST90468685 | 4.37e-05 |
| 11671 | GM3 ganglioside (d18:1/24:0) levels | GCST90024729 | 4.37e-05 |
| 11672 | Pain type(s) experienced in last month - Pain all over the body | Pain | UKBB00000632 | 4.37e-05 |
| 11673 | DIABLO/MITD1 ratio | GCST90314467 | 4.35e-05 |
| 11674 | BSG/PCDH1 ratio | GCST90313535 | 4.34e-05 |
| 11675 | HippSubfield rh volume Hippocampal-tail | GCST90002690 | 4.33e-05 |
| 11676 | NFATC1/TJAP1 ratio | GCST90315540 | 4.32e-05 |
| 11677 | CRTAM/FCRL6 ratio | GCST90314274 | 4.32e-05 |
| 11678 | Free cholesterol in large HDL (UKB data field 23563) | GCST90269660 | 4.25e-05 |
| 11679 | Skin cancer | neoplasms | UKBB00000772 | 4.25e-05 |
| 11680 | Fasting glucose | GCST90002231 | 4.23e-05 |
| 11681 | CDH3/NECTIN4 ratio | GCST90313952 | 4.22e-05 |
| 11682 | Valine levels | GCST90243453 | 4.22e-05 |
| 11683 | DAB2/NCK2 ratio | GCST90314367 | 4.22e-05 |
| 11684 | NOTCH3 levels | GCST90470067 | 4.21e-05 |
| 11685 | TNFRSF13C/TNFSF13B ratio | GCST90315934 | 4.16e-05 |
| 11686 | CASP3/PDGFA ratio | GCST90313637 | 4.11e-05 |
| 11687 | RNF41 levels | GCST90470485 | 4.09e-05 |
| 11688 | DLL1/NBL1 ratio | GCST90314496 | 4.09e-05 |
| 11689 | Primary sclerosing cholangitis | GCST004030 | 4.08e-05 |
| 11690 | Cholesteryl esters in large HDL (UKB data field 23562) | GCST90269659 | 4.05e-05 |
| 11691 | Depressive episode | Mood [affective] disorders | UKBB00000166 | 4.05e-05 |
| 11692 | Cholesterol in large HDL (UKB data field 23561) | GCST90269658 | 4.04e-05 |
| 11693 | ANXA3/ANXA4 ratio | GCST90313278 | 4.04e-05 |
| 11694 | MUC2 levels | GCST90469965 | 4.04e-05 |
| 11695 | DIABLO/GRAP2 ratio | GCST90314466 | 3.98e-05 |
| 11696 | EPHB6 levels | GCST90469133 | 3.96e-05 |
| 11697 | Diseases of middle ear and mastoid | FING00000427 | 3.96e-05 |
| 11698 | CXCL10 levels | GCST90274780 | 3.93e-05 |
| 11699 | ERMAP levels | GCST90469147 | 3.91e-05 |
| 11700 | DAB2/GRAP2 ratio | GCST90314364 | 3.90e-05 |
| 11701 | CCL18/RARRES2 ratio | GCST90313690 | 3.88e-05 |
| 11702 | APRT/CD63 ratio | GCST90313334 | 3.87e-05 |
| 11703 | S100A12 levels | GCST90470513 | 3.87e-05 |
| 11704 | GFER/VASH1 ratio | GCST90314922 | 3.86e-05 |
| 11705 | rfMRI amplitudes (ICA25 node 12) | GCST90004579 | 3.85e-05 |
| 11706 | ITGB1BP2/LAT2 ratio | GCST90315212 | 3.82e-05 |
| 11707 | Free cholesterol levels in large HDL | GCST90092848 | 3.72e-05 |
| 11708 | PSRC1/SORT1 ratio | GCST90315742 | 3.70e-05 |
| 11709 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditions | UKBB00000098 | 3.68e-05 |
| 11710 | Disorders of ocular muscles, binocular movement, accommodation and refraction | FING00000446 | 3.66e-05 |
| 11711 | RETN levels | GCST90012034 | 3.66e-05 |
| 11712 | CEP20 levels | GCST90468712 | 3.63e-05 |
| 11713 | Gastroduodenal ulcer | FING00000565 | 3.61e-05 |
| 11714 | CTSL levels | GCST90012073 | 3.59e-05 |
| 11715 | DLL1 levels | GCST90469004 | 3.58e-05 |
| 11716 | DTI TBSS MD Superior fronto-occipital fasciculus R | GCST90384614 | 3.55e-05 |
| 11717 | OGA levels | GCST90470117 | 3.54e-05 |
| 11718 | Free cholesterol in small HDL | GCST90499425 | 3.51e-05 |
| 11719 | GPI levels | GCST90469391 | 3.49e-05 |
| 11720 | ATP5IF1/METAP1D ratio | GCST90313391 | 3.48e-05 |
| 11721 | PLB1 levels | GCST90470253 | 3.45e-05 |
| 11722 | IDP T1 FAST ROIs L temporal pole | GCST90002465 | 3.45e-05 |
| 11723 | Phospholipids to total lipids ratio in large LDL | GCST90092865 | 3.44e-05 |
| 11724 | LCN2/S100A12 ratio | GCST90315309 | 3.42e-05 |
| 11725 | QDPR levels | GCST90470400 | 3.41e-05 |
| 11726 | IL6 levels | GCST90469604 | 3.38e-05 |
| 11727 | PCDH1/TNFRSF11A ratio | GCST90315608 | 3.35e-05 |
| 11728 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502410 | 3.35e-05 |
| 11729 | TXNRD1 levels | GCST90470994 | 3.34e-05 |
| 11730 | DIABLO levels | GCST90468994 | 3.32e-05 |
| 11731 | FGFR2 levels | GCST90469233 | 3.31e-05 |
| 11732 | SERPINC1 levels | GCST90470594 | 3.29e-05 |
| 11733 | PLA2G15/SMPDL3A ratio | GCST90315663 | 3.28e-05 |
| 11734 | Phosphatidylcholine-O_34:1_[M+H]1+/Phosphatidylcholine-P_34:0_[M+H]1+/Phosphatidylethanolamine-O_37:1_[M+H]1+ levels | GCST90060284 | 3.27e-05 |
| 11735 | PDGFB/PRKAR1A ratio | GCST90315624 | 3.26e-05 |
| 11736 | KLRD1 levels | GCST90469711 | 3.26e-05 |
| 11737 | Allergic conjunctivitis | FING00000067 | 3.23e-05 |
| 11738 | HGFAC levels | GCST90469448 | 3.23e-05 |
| 11739 | CD22/TCL1A ratio | GCST90313760 | 3.22e-05 |
| 11740 | TMSB10/TXNRD1 ratio | GCST90315925 | 3.20e-05 |
| 11741 | CCL17/CCL22 ratio | GCST90313682 | 3.18e-05 |
| 11742 | DNAJB1/PPME1 ratio | GCST90314510 | 3.17e-05 |
| 11743 | Total lipid levels in large HDL | GCST90092850 | 3.16e-05 |
| 11744 | DDX58 levels | GCST90468977 | 3.15e-05 |
| 11745 | Left-hemisphere visual network to left-hemisphere visual network white-matter structural connectivity | GCST90302648 | 3.14e-05 |
| 11746 | TIMD4 levels | GCST90470866 | 3.14e-05 |
| 11747 | DTI TBSS MD Genu of corpus callosum | GCST90384574 | 3.14e-05 |
| 11748 | CXCL11/SDC4 ratio | GCST90314336 | 3.13e-05 |
| 11749 | TNFRSF8/TNFRSF9 ratio | GCST90315940 | 3.13e-05 |
| 11750 | Bursitis (PheCode 726.3) | GCST90476240 | 3.10e-05 |
| 11751 | CIAPIN1/SNAP29 ratio | GCST90314067 | 3.10e-05 |
| 11752 | COPD/asthma/ILD related infections | FING00000353 | 3.09e-05 |
| 11753 | Phospholipids to total lipids ratio in very large HDL | GCST90093013 | 3.06e-05 |
| 11754 | LAT2/SERPINB1 ratio | GCST90315279 | 3.06e-05 |
| 11755 | EFCAB14 levels | GCST90469076 | 3.00e-05 |
| 11756 | APRT/NSFL1C ratio | GCST90313337 | 3.00e-05 |
| 11757 | LRIG1 levels | GCST90469794 | 2.93e-05 |
| 11758 | GPHA2 levels | GCST90469389 | 2.92e-05 |
| 11759 | SEC31A levels | GCST90470563 | 2.89e-05 |
| 11760 | LAMP3 levels | GCST90469735 | 2.88e-05 |
| 11761 | RNASET2 levels | GCST90470481 | 2.81e-05 |
| 11762 | Vitamin D levels | GCST005367 | 2.81e-05 |
| 11763 | ALB levels | GCST90269576 | 2.80e-05 |
| 11764 | IL15/KLRD1 ratio | GCST90315149 | 2.78e-05 |
| 11765 | CLEC1B/DIABLO ratio | GCST90314087 | 2.76e-05 |
| 11766 | Fasting plasma glucose | GCST90566420 | 2.74e-05 |
| 11767 | AK1 levels | GCST90468269 | 2.74e-05 |
| 11768 | Alkaline phosphatase | Blood biochemistry | UKBB00000027 | 2.73e-05 |
| 11769 | F11R/SORT1 ratio | GCST90314726 | 2.73e-05 |
| 11770 | GOLM2/STC1 ratio | GCST90314952 | 2.69e-05 |
| 11771 | Inflammatory bowel disease | GCST90432182 | 2.67e-05 |
| 11772 | SCARB2 levels | GCST90470535 | 2.67e-05 |
| 11773 | DKK1/PTPN6 ratio | GCST90314478 | 2.66e-05 |
| 11774 | Acetone levels (UKB data field 23477) | GCST90269574 | 2.64e-05 |
| 11775 | Mean corpuscular volume | GCST90002335 | 2.64e-05 |
| 11776 | IGF2R levels | GCST90469526 | 2.63e-05 |
| 11777 | ABHD14B/SPARC ratio | GCST90313146 | 2.61e-05 |
| 11778 | OGFR levels | GCST90470118 | 2.57e-05 |
| 11779 | Lymphocyte count | Blood count | UKBB00000411 | 2.55e-05 |
| 11780 | IFNG levels | GCST90469515 | 2.55e-05 |
| 11781 | IPCEF1/SERPINE1 ratio | GCST90315184 | 2.54e-05 |
| 11782 | STC1 levels | GCST90470761 | 2.54e-05 |
| 11783 | Gestational diabetes mellitus | GCST90566419 | 2.54e-05 |
| 11784 | Lymphocyte percentage of white cells | GCST004632 | 2.52e-05 |
| 11785 | Clonal haematopoiesis of indeterminate potential (with or without mosaic chromosomal alteration) | GCST90165267 | 2.50e-05 |
| 11786 | ADA2/VCAM1 ratio | GCST90313167 | 2.49e-05 |
| 11787 | NID1/NID2 ratio | GCST90315541 | 2.48e-05 |
| 11788 | MYH9 levels | GCST90469975 | 2.46e-05 |
| 11789 | Acquired hypothyroidism (PheCode 244.2) | GCST90475650 | 2.46e-05 |
| 11790 | IGF2R/RNASET2 ratio | GCST90315132 | 2.44e-05 |
| 11791 | IDP dMRI TBSS L1 Retrolenticular part of internal capsule L | GCST90004096 | 2.44e-05 |
| 11792 | JAM2/TNFRSF14 ratio | GCST90315240 | 2.41e-05 |
| 11793 | CXCL3/CXCL5 ratio | GCST90314344 | 2.41e-05 |
| 11794 | Volume of left accessory basal nucleus | GCST90474874 | 2.41e-05 |
| 11795 | TXNDC15 levels | GCST90470990 | 2.41e-05 |
| 11796 | CSF1R levels | GCST90468880 | 2.40e-05 |
| 11797 | F2R/MPIG6B ratio | GCST90314732 | 2.38e-05 |
| 11798 | BSG/LY9 ratio | GCST90313534 | 2.37e-05 |
| 11799 | Lymphocyte count | GCST90002316 | 2.37e-05 |
| 11800 | SCRN1 levels | GCST90470556 | 2.37e-05 |
| 11801 | CNTNAP2 levels | GCST90468808 | 2.35e-05 |
| 11802 | Acute renal failure | FING00000030 | 2.34e-05 |
| 11803 | WASHC3 levels | GCST90471069 | 2.33e-05 |
| 11804 | CLEC4D/TGFA ratio | GCST90314117 | 2.31e-05 |
| 11805 | N-acetyl-1-methylhistidine levels | GCST90200690 | 2.31e-05 |
| 11806 | HPCAL1/SERPINB9 ratio | GCST90315079 | 2.30e-05 |
| 11807 | Other noninfective gastroenteritis and colitis | FING00001077 | 2.30e-05 |
| 11808 | CD207 levels | GCST90468607 | 2.29e-05 |
| 11809 | Oral glucose tolerance test-1h | GCST90566422 | 2.28e-05 |
| 11810 | Sexual abuse | GCST90551837 | 2.28e-05 |
| 11811 | Omega-3 fatty acid levels | GCST90502441 | 2.27e-05 |
| 11812 | CDHR1 levels | GCST90468678 | 2.27e-05 |
| 11813 | Type 1 diabetes | GCST90000529 | 2.27e-05 |
| 11814 | Free cholesterol in very large HDL | GCST90500383 | 2.27e-05 |
| 11815 | NSFL1C/UBAC1 ratio | GCST90315565 | 2.26e-05 |
| 11816 | Ulcerative colitis | GCST90475322 | 2.26e-05 |
| 11817 | Crohn's disease | GCST004132 | 2.26e-05 |
| 11818 | EGF/MGLL ratio | GCST90314610 | 2.25e-05 |
| 11819 | S100G levels | GCST90470519 | 2.25e-05 |
| 11820 | Mean reticulocyte volume | GCST90025975 | 2.24e-05 |
| 11821 | ITGB7 levels | GCST90469647 | 2.23e-05 |
| 11822 | SFTPA2 levels | GCST90470613 | 2.22e-05 |
| 11823 | PDGFB/SDC4 ratio | GCST90315626 | 2.22e-05 |
| 11824 | DRG2 levels | GCST90469039 | 2.20e-05 |
| 11825 | TFPI2 levels | GCST90470838 | 2.19e-05 |
| 11826 | Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044) | GCST90042535 | 2.19e-05 |
| 11827 | Alanine aminotransferase levels | GCST90018723 | 2.17e-05 |
| 11828 | Histidine levels | GCST90243404 | 2.17e-05 |
| 11829 | PDGFB/TNFSF13 ratio | GCST90315632 | 2.16e-05 |
| 11830 | Phospholipid levels in large HDL | GCST90092852 | 2.15e-05 |
| 11831 | high density lipoprotein cholesterol (HDLC, mean, inv-norm transformed) | GCST90475352 | 2.14e-05 |
| 11832 | PPIF levels | GCST90470293 | 2.13e-05 |
| 11833 | CEP43/MPHOSPH8 ratio | GCST90314019 | 2.13e-05 |
| 11834 | CD84/GP6 ratio | GCST90313914 | 2.13e-05 |
| 11835 | Cervical cancer | GCST90018597 | 2.13e-05 |
| 11836 | APBB1IP levels | GCST90468327 | 2.12e-05 |
| 11837 | APRT/PSME1 ratio | GCST90313338 | 2.11e-05 |
| 11838 | SDC4/SMAD1 ratio | GCST90315820 | 2.11e-05 |
| 11839 | L1CAM/SEZ6L ratio | GCST90315266 | 2.10e-05 |
| 11840 | EDAR/F2R ratio | GCST90314577 | 2.09e-05 |
| 11841 | GRAP2/PLPBP ratio | GCST90314984 | 2.06e-05 |
| 11842 | ABHD14B levels | GCST90468189 | 2.06e-05 |
| 11843 | ABHD14B/CCS ratio | GCST90313139 | 2.05e-05 |
| 11844 | GMFG levels | GCST90469366 | 2.04e-05 |
| 11845 | Urinary tryptophan to urinary creatinine ratio | GCST90451748 | 2.04e-05 |
| 11846 | Lysophosphatidylethanolamine-P_20:0_[M-H]1- levels | GCST90060147 | 2.03e-05 |
| 11847 | FABP4/FGF21 ratio | GCST90314758 | 2.03e-05 |
| 11848 | EGF/GP6 ratio | GCST90314608 | 2.02e-05 |
| 11849 | Chronic iridocyclitis | FING00000287 | 2.01e-05 |
| 11850 | DNMBP/WWP2 ratio | GCST90314522 | 1.99e-05 |
| 11851 | AGRN/HSPG2 ratio | GCST90313201 | 1.98e-05 |
| 11852 | ARSB levels | GCST90468369 | 1.95e-05 |
| 11853 | CCL11/CCL7 ratio | GCST90313673 | 1.95e-05 |
| 11854 | Acute myocardial infarction | Ischaemic heart diseases | UKBB00000011 | 1.94e-05 |
| 11855 | Cholesteryl ester (16:2) levels | GCST90025238 | 1.91e-05 |
| 11856 | EGF/MPIG6B ratio | GCST90314611 | 1.89e-05 |
| 11857 | Omega-3 fatty acids to total fatty acids percentage | GCST90502467 | 1.88e-05 |
| 11858 | Phospholipids in large LDL | GCST90498049 | 1.87e-05 |
| 11859 | CRTAM/LY9 ratio | GCST90314278 | 1.86e-05 |
| 11860 | Vitamin B12 deficiency anaemia | FING00001441 | 1.85e-05 |
| 11861 | CD69/CLEC1B ratio | GCST90313869 | 1.85e-05 |
| 11862 | Pyruvate levels (UKB data field 23472) | GCST90269569 | 1.83e-05 |
| 11863 | DBNL levels | GCST90468951 | 1.82e-05 |
| 11864 | CD22/SEMA7A ratio | GCST90313759 | 1.82e-05 |
| 11865 | REG1B levels | GCST90470448 | 1.81e-05 |
| 11866 | AXIN1/NFATC1 ratio | GCST90313415 | 1.79e-05 |
| 11867 | ABL1/DNMBP ratio | GCST90313149 | 1.79e-05 |
| 11868 | DAG1/DKK1 ratio | GCST90314373 | 1.79e-05 |
| 11869 | YWHAQ levels | GCST90471092 | 1.77e-05 |
| 11870 | MMP8 levels | GCST90469922 | 1.76e-05 |
| 11871 | SRSF7 levels | GCST90242771 | 1.74e-05 |
| 11872 | Crohn's disease NAS | FING00000367 | 1.74e-05 |
| 11873 | CNTN3/FETUB ratio | GCST90314164 | 1.71e-05 |
| 11874 | AK1/PEBP1 ratio | GCST90313225 | 1.71e-05 |
| 11875 | FGA levels | GCST90469216 | 1.71e-05 |
| 11876 | PRKAB1 levels | GCST90470324 | 1.70e-05 |
| 11877 | ALB levels | GCST90497101 | 1.69e-05 |
| 11878 | Coriander liking | GCST90094744 | 1.69e-05 |
| 11879 | DPEP1 levels | GCST90469030 | 1.69e-05 |
| 11880 | CCL17/F2R ratio | GCST90313686 | 1.69e-05 |
| 11881 | F2R/SERPINE1 ratio | GCST90314735 | 1.69e-05 |
| 11882 | APOD levels | GCST90468337 | 1.67e-05 |
| 11883 | Thyroiditis, unspecified | FING00001359 | 1.67e-05 |
| 11884 | CCL14 levels | GCST90468566 | 1.66e-05 |
| 11885 | DAG1/PDGFA ratio | GCST90314378 | 1.65e-05 |
| 11886 | CD209 levels | GCST90468608 | 1.61e-05 |
| 11887 | TXNL1 levels | GCST90470993 | 1.60e-05 |
| 11888 | Medication use (immunosuppressants) | GCST90018771 | 1.60e-05 |
| 11889 | ALB/Globulin ratio | UKBB00000020 | 1.59e-05 |
| 11890 | Malignant neoplasm of lip, excluding all cancers (controls excluding all cancers) | FING00000764 | 1.58e-05 |
| 11891 | IGF1 levels | GCST90025989 | 1.57e-05 |
| 11892 | DLK1/RGMB ratio | GCST90314493 | 1.56e-05 |
| 11893 | Free cholesterol in very large HDL (UKB data field 23556) | GCST90269653 | 1.56e-05 |
| 11894 | DNAJA2/PLXNA4 ratio | GCST90314504 | 1.56e-05 |
| 11895 | Hypothyroidism | GCST90319320 | 1.53e-05 |
| 11896 | DPP7 levels | GCST90469035 | 1.52e-05 |
| 11897 | SNX9/VASH1 ratio | GCST90315866 | 1.51e-05 |
| 11898 | CFC1 levels | GCST90468724 | 1.51e-05 |
| 11899 | X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels | GCST90243619 | 1.49e-05 |
| 11900 | NCR1 levels | GCST90470009 | 1.48e-05 |
| 11901 | ENG/PEAR1 ratio | GCST90314649 | 1.46e-05 |
| 11902 | KITLG levels | GCST90012023 | 1.45e-05 |
| 11903 | Thyroid stimulating hormone levels within normal range in pregnancy | GCST90435195 | 1.45e-05 |
| 11904 | GIPC2 levels | GCST90469347 | 1.45e-05 |
| 11905 | MPIG6B/PLXNA4 ratio | GCST90315483 | 1.44e-05 |
| 11906 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502398 | 1.43e-05 |
| 11907 | CA5A/GRPEL1 ratio | GCST90313590 | 1.43e-05 |
| 11908 | ANPEP/NT5E ratio | GCST90313274 | 1.43e-05 |
| 11909 | CCL19 levels | GCST90468571 | 1.42e-05 |
| 11910 | GORASP2 levels | GCST90469378 | 1.41e-05 |
| 11911 | ITIH3 levels | GCST90469650 | 1.40e-05 |
| 11912 | TNFSF14 levels | GCST90470922 | 1.39e-05 |
| 11913 | Ulcerative colitis | GCST90446795 | 1.38e-05 |
| 11914 | LY6D/WFDC12 ratio | GCST90315346 | 1.37e-05 |
| 11915 | DTI autoptx L2 fmi tract | GCST90385177 | 1.35e-05 |
| 11916 | TGOLN2 levels | GCST90470850 | 1.33e-05 |
| 11917 | CAPS levels | GCST90468539 | 1.33e-05 |
| 11918 | GZMA/LTA ratio | GCST90315012 | 1.33e-05 |
| 11919 | PZP levels | GCST90470399 | 1.31e-05 |
| 11920 | Volume of left anterior amygdaloid area | GCST90474937 | 1.30e-05 |
| 11921 | Ulcerative colitis | GCST004133 | 1.29e-05 |
| 11922 | Mean corpuscular volume | GCST90018746 | 1.29e-05 |
| 11923 | Regional enteritis (PheCode 555.1) | GCST90476066 | 1.28e-05 |
| 11924 | RNF149 levels | GCST90470482 | 1.26e-05 |
| 11925 | CD84/DKK1 ratio | GCST90313911 | 1.25e-05 |
| 11926 | SLAMF7 levels | GCST90470651 | 1.25e-05 |
| 11927 | Average diameter for HDL particles (UKB data field 23433) | GCST90269530 | 1.24e-05 |
| 11928 | CRTAM levels | GCST90468871 | 1.23e-05 |
| 11929 | EIF4E levels | GCST90469096 | 1.23e-05 |
| 11930 | IL1RN levels | GCST90012004 | 1.23e-05 |
| 11931 | DBNL/PDGFB ratio | GCST90314422 | 1.23e-05 |
| 11932 | Urine betaine levels in chronic kidney disease | GCST90264859 | 1.21e-05 |
| 11933 | IDP dMRI TBSS ISOVF Sagittal stratum R | GCST90004507 | 1.20e-05 |
| 11934 | SKAP2 levels | GCST90470646 | 1.19e-05 |
| 11935 | PLAU/PLAUR ratio | GCST90315674 | 1.19e-05 |
| 11936 | TPP1 levels | GCST90470946 | 1.16e-05 |
| 11937 | TBC1D23 levels | GCST90470810 | 1.16e-05 |
| 11938 | CD27/NECTIN4 ratio | GCST90313775 | 1.16e-05 |
| 11939 | BLOC1S3 levels | GCST90468450 | 1.16e-05 |
| 11940 | F9/FURIN ratio | GCST90314747 | 1.16e-05 |
| 11941 | GALNT10/TNFSF12 ratio | GCST90314916 | 1.15e-05 |
| 11942 | EBAG9/TGFB1 ratio | GCST90314570 | 1.15e-05 |
| 11943 | BGN levels | GCST90468441 | 1.15e-05 |
| 11944 | Gout | GCST90399700 | 1.15e-05 |
| 11945 | ADGRE5/ITGB2 ratio | GCST90313180 | 1.13e-05 |
| 11946 | IL5RA/TNFRSF13B ratio | GCST90315164 | 1.13e-05 |
| 11947 | CA6/DNER ratio | GCST90313594 | 1.12e-05 |
| 11948 | KLB levels | GCST90469693 | 1.12e-05 |
| 11949 | Left-hemisphere dorsal attention network to left-hemisphere default mode network white-matter structural connectivity | GCST90302693 | 1.11e-05 |
| 11950 | TALDO1 levels | GCST90470802 | 1.11e-05 |
| 11951 | Free Cholesterol to Total Lipids in Small HDL percentage | GCST90499436 | 1.10e-05 |
| 11952 | Fracture of radius and ulna (PheCode 803.2) | GCST90476280 | 1.09e-05 |
| 11953 | ABHD14B/APRT ratio | GCST90313137 | 1.09e-05 |
| 11954 | RNF41/WWP2 ratio | GCST90315782 | 1.09e-05 |
| 11955 | CD63 levels | GCST90468642 | 1.08e-05 |
| 11956 | Cholesteryl esters in very large HDL (UKB data field 23555) | GCST90269652 | 1.06e-05 |
| 11957 | Crohn's disease of large intestine | FING00000368 | 1.06e-05 |
| 11958 | CCL3 levels | GCST90468582 | 1.06e-05 |
| 11959 | TNFRSF13C levels | GCST90470906 | 1.05e-05 |
| 11960 | Blood cell traits latent factor 8 (white cell) | GCST90559250 | 1.05e-05 |
| 11961 | CCL26 levels | GCST90468578 | 1.04e-05 |
| 11962 | PLIN3/TYMP ratio | GCST90315678 | 1.04e-05 |
| 11963 | HAVCR2/TNFRSF1B ratio | GCST90315030 | 1.03e-05 |
| 11964 | OMD/SPP1 ratio | GCST90315586 | 1.03e-05 |
| 11965 | Hypothyroidism | GCST90468138 | 1.03e-05 |
| 11966 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 77) | GCST90320896 | 1.02e-05 |
| 11967 | GZMH/KLRD1 ratio | GCST90315016 | 1.02e-05 |
| 11968 | Iridocyclitis | FING00000696 | 1.01e-05 |
| 11969 | Phenylalanine levels | GCST90499228 | 1.00e-05 |
| 11970 | BACH1/DIABLO ratio | GCST90313437 | 1.00e-05 |
| 11971 | TNFSF12 levels | GCST90274846 | 9.95e-06 |
| 11972 | CRKL/SERPINB1 ratio | GCST90314272 | 9.91e-06 |
| 11973 | BCL2 levels | GCST90468433 | 9.81e-06 |
| 11974 | DBNL/VASH1 ratio | GCST90314427 | 9.73e-06 |
| 11975 | Inflammatory bowel disease, strict (require KELA) | FING00000675 | 9.71e-06 |
| 11976 | IPCEF1 levels | GCST90469624 | 9.71e-06 |
| 11977 | Eczema | GCST90468126 | 9.61e-06 |
| 11978 | CCL18 levels | GCST90468570 | 9.53e-06 |
| 11979 | Primary biliary cholangitis | GCST003129 | 9.43e-06 |
| 11980 | CHI3L1 levels | GCST90468743 | 9.41e-06 |
| 11981 | Phospholipid levels in very large HDL | GCST90093012 | 9.38e-06 |
| 11982 | CD244 levels | GCST90274771 | 9.18e-06 |
| 11983 | Acetone levels | GCST90092805 | 9.17e-06 |
| 11984 | CRELD2/TXNDC5 ratio | GCST90314259 | 9.16e-06 |
| 11985 | PLCB2 levels | GCST90470255 | 9.13e-06 |
| 11986 | FOLH1 levels | GCST90427192 | 9.08e-06 |
| 11987 | DARS1/EIF4B ratio | GCST90314403 | 9.01e-06 |
| 11988 | ADGRB3 levels | GCST90468234 | 8.98e-06 |
| 11989 | Skin luminance | GCST90320257 | 8.90e-06 |
| 11990 | MPIG6B/PDGFB ratio | GCST90315482 | 8.81e-06 |
| 11991 | CD302/CD99 ratio | GCST90313805 | 8.77e-06 |
| 11992 | Hypothyroidism, strict autoimmune | FING00000656 | 8.74e-06 |
| 11993 | NRGN levels | GCST90470083 | 8.72e-06 |
| 11994 | CST7 levels | GCST90468897 | 8.69e-06 |
| 11995 | Human herpes virus 7 U14 antibody levels | GCST90006909 | 8.66e-06 |
| 11996 | MECR levels | GCST90469879 | 8.65e-06 |
| 11997 | HBEGF levels | GCST90012067 | 8.61e-06 |
| 11998 | ERP44 levels | GCST90469150 | 8.52e-06 |
| 11999 | BIN2 levels | GCST90468445 | 8.48e-06 |
| 12000 | Mean platelet volume | GCST90002395 | 8.47e-06 |